# Evaluation of the Immunogenicity and Safety of Ad26.COV2.S's COVID-19 Vaccine

> **NCT05409261** · PHASE2 · UNKNOWN · sponsor: **ANRS, Emerging Infectious Diseases** · enrollment: 200 (actual)

## Conditions studied

- COVID-19
- Vaccine Reaction
- SARS CoV 2 Infection
- Vaccine Adverse Reaction

## Interventions

- **BIOLOGICAL:** Ad26.COV2.S

## Key facts

- **NCT ID:** NCT05409261
- **Lead sponsor:** ANRS, Emerging Infectious Diseases
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-06-02
- **Primary completion:** 2022-09-25
- **Final completion:** 2025-03
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2024-03-27

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05409261

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05409261, "Evaluation of the Immunogenicity and Safety of Ad26.COV2.S's COVID-19 Vaccine". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05409261. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*